RecruitingNCT03117036

Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center

Sponsor

Samsung Medical Center

Enrollment

600 participants

Start Date

Mar 1, 2017

Study Type

OBSERVATIONAL

Conditions

Lymphoma, Non-Hodgkin Lymphoma, Hodgkin

Summary

This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

Eligibility

Min Age: 20 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is tracking a large group of lymphoma patients over time to better understand the disease, how it responds to treatment, and what factors affect outcomes. **You may be eligible if...** - You have been diagnosed with Hodgkin lymphoma or non-Hodgkin lymphoma (confirmed by a pathology test) - You are 20 years old or older - You need chemotherapy with the goal of curing your cancer - You are willing to sign a consent form **You may NOT be eligible if...** - You have a blood cancer that starts in myeloid cells (such as AML or MDS) - You have multiple myeloma - Your treatment plan does not include chemotherapy aimed at a cure Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.